Basic Information
ID: ALA4158585
Type: Toxicity
Description: Therapeutic index, ratio of CC50 for human Hep2 cells to EC50 for inhibition of RSV long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells
Format: BAO_0000219
Target: ADMET(ALA612558)
Document: ALA4152381
Therapeutic index, ratio of CC50 for human Hep2 cells to EC50 for inhibition of RSV long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells: 1
Activity Charts
Bioactivity
Activity Types for Assay ALA4158585
Ratio CC50/EC50
Compound Summary
| Parent Molecular Weight | ALogP | Polar Surface Area |
|---|---|---|
| 346.48 | 3.87 | 3.87 |
| 406.51 | 4.18 | 4.18 |
| 346.48 | 3.95 | 3.95 |
| 365.45 | 4.04 | 4.04 |
| 392.52 | 4.78 | 4.78 |
| 334.42 | 3.00 | 3.00 |
| 420.53 | 4.04 | 4.04 |
| 432.59 | 5.53 | 5.53 |
| 332.45 | 3.56 | 3.56 |
| 438.60 | 3.88 | 3.88 |
| 361.45 | 2.88 | 2.88 |
| 334.42 | 2.49 | 2.49 |
| 378.45 | 3.53 | 3.53 |
| 362.48 | 3.57 | 3.57 |
| 433.58 | 3.95 | 3.95 |
| 332.45 | 3.56 | 3.56 |
| 410.54 | 3.10 | 3.10 |
| 396.52 | 2.71 | 2.71 |
| 410.54 | 2.96 | 2.96 |
| 366.90 | 4.21 | 4.21 |
| 382.46 | 4.42 | 4.42 |
| 349.43 | 2.56 | 2.56 |
| 418.56 | 5.19 | 5.19 |
| 350.44 | 3.70 | 3.70 |
| 378.50 | 4.27 | 4.27 |
| 392.52 | 4.78 | 4.78 |
| 318.42 | 3.17 | 3.17 |
| 378.50 | 4.39 | 4.39 |
| 364.47 | 4.01 | 4.01 |
| 382.49 | 2.40 | 2.40 |
| 434.56 | 4.38 | 4.38 |
| 366.90 | 4.21 | 4.21 |
| 378.50 | 4.39 | 4.39 |
| 348.45 | 2.53 | 2.53 |
| 364.47 | 4.01 | 4.01 |
| 366.90 | 4.21 | 4.21 |
| 366.90 | 4.21 | 4.21 |
| 406.51 | 3.77 | 3.77 |
| 362.48 | 2.92 | 2.92 |
| 378.45 | 3.53 | 3.53 |
| 333.43 | 3.59 | 3.59 |
| 424.57 | 3.49 | 3.49 |
| 400.45 | 4.58 | 4.58 |
| 360.46 | 2.69 | 2.69 |
| 392.52 | 4.61 | 4.61 |
| 406.51 | 3.77 | 3.77 |
| 361.45 | 2.87 | 2.87 |
| 347.47 | 3.35 | 3.35 |